The iiMedia Ranking · 2025 China Innovative Drugs Global Expansion Leadership Ranking made its grand debut in Singapore. As the co-publisher and strategic partner, Stellar Biotech leveraged its professional service network deeply rooted in Southeast Asia to help Chinese innovative pharma companies establish a strong presence in Singapore and build a regional pharmaceutical hub. The ranking brings together China’s innovative drug “national team” including 3SBio, Innovent Biologics, and Sinopharm Group, highlighting Singapore’s strategic value as the “premier gateway” for Chinese innovative drugs going global and opening a new chapter in China-Singapore pharmaceutical industry cooperation.

The world’s first professional ranking focused on innovative drug global expansion — iiMedia Ranking · 2025 China Innovative Drugs Global Expansion Leadership Ranking — was officially released in Singapore on November 17, 2025. As an authoritative evaluation system under iiMedia Research, the ranking is supported by the self-developed CMDAS big data system and features an original four-dimensional evaluation model: Technical Barriers + Global Progress + Commercialization Potential + Regional Implementation Capability. From nearly 4,000 Chinese pharmaceutical enterprises, it precisely selected the Top 40 Leading Enterprises, including: WuXi AppTec, BeiGene, CSPC Pharmaceutical, Sinopharm Group, Kelun Pharmaceutical, Shanghai Pharmaceuticals, Baili Tianheng, 3SBio, Ascentage Pharma, United Laboratories, Hengrui Medicine, Fosun Pharma, Huadong Medicine, Sinovac Biotech, Legend Biotech, Hansoh Pharma, Healthcare, Yifan Pharmaceutical, Innovent Biologics, Akeso Biologics, Junshi Biosciences, Zai Lab, Gan & Lee Pharmaceuticals, Rongchang Biologics, GenSci, Porton Pharma, YingEn Biologics, Everest Medicines, Hutchison MediPharma, Simcere Pharmaceutical, Deqiao Therapeutics, Aosaikang, Lepu Biologics, Jacobi Therapeutics, I-Mab, Dizal Pharma, 3D Medicines, Harbour BioMed, Lavel Biotech, PuraPharm Biologics.

As of November 18, 2025, the total transaction value of China’s innovative drug license-out deals exceeded USD 103.43 billion, representing a 90.51% year-on-year surge from USD 54.29 billion in the full year of 2024. Nearly 80% of this transaction volume came from enterprises on this ranking.

The debut of the iiMedia Ranking in Singapore underscores the city‑state’s role as the core pharmaceutical hub in Southeast Asia, carrying profound strategic significance. This platform positions Singapore as a strategic hub connecting Chinese innovative drugs with global markets, strengthens Asia‑Pacific influence in the global pharmaceutical innovation landscape, channels high‑quality Chinese innovative resources into Singapore’s biopharmaceutical industry, and promotes two‑way flow of technology and capital. Meanwhile, through Singapore as a “springboard”, Chinese innovative pharma enterprises can rapidly expand to 10 Southeast Asian countries, Australia and New Zealand, forming a full‑chain layout of R&D — Registration — Commercialization.

As the exclusive strategic partner of the ranking, Stellar Biotech provides one-stop services from regulatory registration to commercialization for listed enterprises, supported by its strong “dual headquarters + full regional coverage” network and extensive international registration experience. Its core services cover key links including regional registration applications, localized distribution network construction, and cross-border cold-chain logistics support, efficiently solving localization challenges for Chinese pharma companies going global.

This empowerment model delivers tangible value to Singapore: The entry of Chinese innovative pharma enterprises drives growth in pharmaceutical-related businesses and creates high-skilled jobs; project implementation and market operations directly contribute to tax revenue, injecting new momentum into Singapore’s economy. More importantly, as an innovative practice of the “professional ranking + market empowerment” model, Stellar Biotech, as the core enabler, transforms the “evaluation value” of the ranking into “implementation value”. By jointly organizing Southeast Asia compliance salons, government-enterprise matchmaking meetings, and clinical resource matching sessions, Stellar Biotech helps listed enterprises quickly understand regional market rules. This collaborative model extends the industry influence of the ranking through Stellar Biotech’s on-the-ground services, further elevating Singapore’s reputation as a pharmaceutical service hub.

Mr. Lin, Chairman of Stellar Biotech, stated:"We are committed to building Singapore into the preferred gateway for Chinese innovative drugs going global.Through Stellar Biotech’s localized service network, Chinese pharma enterprises can achieve the efficient expansion model of 'Registered in Singapore, Sold Across Southeast Asia', greatly lowering the threshold for internationalization."

With five core advantages, Singapore has become the preferred strategic hub for Chinese innovative drugs to deploy in Southeast Asia:

With the release of the iiMedia Ranking · 2025 China Innovative Drugs Global Expansion Leadership Ranking and the professional empowerment of Stellar Biotech, Chinese innovative drugs are accelerating entry into the vast blue-ocean market of Southeast Asia. This cross-border cooperation model not only establishes Singapore as a transit hub for Chinese innovative drugs but also fosters a pharmaceutical ecosystem featuring agglomerated innovative resources, complete industrial services, and extensive market reach. As more top Chinese innovative pharma enterprises land in Singapore through Stellar Biotech, Singapore will further attract pharmaceutical industrial chain resources across the region, consolidate its core position as a pharmaceutical R&D, distribution and logistics hub in Southeast Asia, and inject sustained impetus into the nation’s long-term development.

Scan to follow